Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis

  • Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
/by
Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer

Novartis Kisqali® NATALEE analysis reinforces consistent reduction in risk of recurrence across key subgroups of patients with early breast cancer
arcticnovartis

  • Late-breaking NATALEE subgroup analysis to be presented at ESMO shows invasive disease-free survival (iDFS) benefit remains consistent in all subgroups, including in patients with stage II tumors, node-negative disease and those who are 65 or older1
/by
Violence against innocent people runs counter to our work to improve human health

Violence against innocent people runs counter to our work to improve human health
angilma1

/by
Violence against innocent people runs counter to our work to improve human health

Violence against innocent people runs counter to our work to improve human health
angilma1

/by
Novartis condemns the terrorist actions against people in Israel and loss of innocent lives

Novartis condemns the terrorist actions against people in Israel and loss of innocent lives
weberfr8

/by
Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer

Novartis to present new oncology data at ESMO 2023 demonstrating practice-changing innovation in advanced prostate and early breast cancer
arcticnovartis

  • Key data from the Phase III PSMAfore trial has been selected for a Presidential session; PSMAfore is investigating PluvictoTM(INN: lutetium (177Lu) vipivotide tetraxetan) in the pre-chemotherapy setting for patients with PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)
  • New analysis of key subgroups of clinical interest from NATALEE reinforces the potential of Kisqali®(ribociclib) plus endocrine therapy (ET) to consistently reduce the risk of cancer recurrence across a broad popu
/by
Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company

Novartis executes Sandoz Spin-off, completing strategic transformation into a leading, focused innovative medicines company
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR 

/by
Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)

Novartis investigational iptacopan Phase III study demonstrates clinically meaningful and highly statistically significant proteinuria reduction in patients with IgA nephropathy (IgAN)
arcticnovartis

Ad hoc announcement pursuant to Art. 53 LR

/by
Novartis completes divestment of ‘front of eye’ ophthalmology assets

Novartis completes divestment of ‘front of eye’ ophthalmology assets
arcticnovartis

  • Divestment includes Xiidra®, on-market treatment for dry eye disease and additional ophthalmic investigational therapies
  • Novartis advances strategy of focused portfolio and prioritized therapeutic areas for future growth

Basel, September 29th, 2023 — Novartis today announced that it has completed its divestment of ‘front of eye’ ophthalmology assets to Bausch + Lomb, a global eye health company, in a transaction valued up to USD 2.5 billion, consisting of 1.75 billion in upfront cash, plus potential add

/by
Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe

Sandoz receives European Commission approval for Tyruko® (natalizumab), first and only biosimilar for multiple sclerosis in Europe
arcticnovartis

  • Biosimilar Tyruko® approved for all indications of reference medicine, as first and only biosimilar to treat relapsing forms of multiple sclerosis (MS) in Europe
  • Decision based on evidence from extensive analytical characterization demonstrating similarity of biosimilar with reference biologic, in addition to Phase I and confirmatory Phase III studies.
/by